Spotlight Stocks: CIT Group, DuPont, Texas Instruments, United Health

Tuesday's top stories and stocks with potential to move.

Stay Connected

Stocks to watch for Tuesday, April 22, 2008:

Boston Scientific (BSX) reported 1Q net income of $322 million, or 21 cents a share, more than twice the year ago results of $120 million, or 8 cents a share. Sales at the company fell 1.9% to $2.05 billion. The numbers were helped by cost cuts, including a plan to slash 2,300 jobs.

CIT Group (CIT) said it sold $1.5 billion of common stock and convertible preferred stock. According to Reuters, this is 50% more than the company had planned to sell and further dilutes existing shareholders. $1 billion was sold as 91 million shares of common stock at $11 each. $500 million was in preferred stock carrying an 8.75% dividend, convertible into CIT stock at $12.65 apiece.

DuPont (DD) posted 1Q net income of $1.19 billion, or $1.31 a share, up from $945 million, or $1.01 a share a year ago. The company said results were helped by growing food demand in developing countries and increased use of biofuels which have led to soaring grain prices and the increased use of fertilizer and high-yielding biotech seeds, reported Reuters.

Fifth Third Bancorp (FITB) reported 1q net income of $292 million, or 55 cents a share, down 19% from $359 million, or 65 cents a share a year ago. Revenue climbed 26% to $1.7 billion. According to The Wall Street Journal, the bank boosted its provision for loan and lease losses more than sixfold to $544 million.

Texas Instruments (TXN) reported 1Q profit of $662 million, or 49 cents a share, a 28% gain from a year ago and in line with expectations. Revenue came in at $3.27 billion. However, shares dipped as the company commented on a weak market for high-end mobile phone chips.

United Health (UNH) reported 1Q net income of $994 million, or 78 cents a share, a 7.2% increase from $927 million, or 66 cents a share a year ago. Revenue was up 6.6% to $20.3 billion from $19.05 billion. Despite the numbers, the company cut its forecast for full-year earnings by 40 cents to a range of $3.55 to $3.60 a share, including an expected 10-cent negative impact of "unusually high influenza costs." It also cut its revenue outlook to between $81 billion and $82 billion from $83 billion, said the WSJ.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.